Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Expedia Group Inc (EXPE) Price & Performance

AbCellera Biologics IncTrade
Expedia Group IncTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Expedia Group Inc — how do they compare? AbCellera Biologics Inc trades at $9.13 (market cap $2.99B), while Expedia Group Inc trades at $321 (market cap $38.53B). The key difference: Expedia Group Inc is far larger — about 12.9× AbCellera Biologics Inc's market cap, and Expedia Group Inc pays a 0.6% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.

ABCLEXPE
Market Cap
$2.99B$38.53B
Sector
HealthConsumer Cyclical
52-Week High
$9.76$321.07
52-Week Low
$2.78$188.51
Enterprise Value
$2.58B$37.09B
Dividend Yield
0.6%

Returns comparison

Trailing returns across standard periods

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Expedia Group Inc

Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.

Read more on EXPE